In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 26 to 50 of 425

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]	Technology appraisal guidance	TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]	Technology appraisal guidance	TBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]	Technology appraisal guidance	TBC
Atogepant for treating migraine [ID6615]	Technology appraisal guidance	TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance	TBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]	Technology appraisal guidance	3 September 2026
Avelumab for previously treated platinum-resistant ovarian cancer ID1497	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]	Technology appraisal guidance	TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]	Technology appraisal guidance	TBC
Balloon cryoablation for treating Barrett's oesophagus	Interventional procedures guidance	29 January 2026
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]	Technology appraisal guidance	TBC
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]	Technology appraisal guidance	TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]	Technology appraisal guidance	TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]	Technology appraisal guidance	21 January 2026
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]	Technology appraisal guidance	11 February 2026
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]	Technology appraisal guidance	TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]	Technology appraisal guidance	8 December 2027
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]	Technology appraisal guidance	13 January 2027
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance	TBC

Results per page

10
25
50
All